A Randomized, Open, Controlled, Multi-Centre, Phase II Clinical Study to Evaluate the Efficacy and Safety of ACT001 Monotherapy and the Combination of ACT001 with Temozolomide VS Temozolomide or Lomustine Alone in Patients with Recurrent Glioblastoma
Latest Information Update: 03 Dec 2020
At a glance
- Drugs ACT 001 (Primary) ; Lomustine; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
Most Recent Events
- 03 Dec 2020 New trial record